IP Library Granted Patent US 7,364,869
Granted Patent B2
US 7,364,869 · App. 10/895,239 · Granted Apr 29, 2008

Method of detecting antigen-specific T lymphocytes

Assignee: The J. David Gladstone Institutes
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,364,869
App. No.
10/895,239
Granted
Apr 29, 2008
Kind
B2
Abstract

The present invention provides a method of detecting antigen-specific T lymphocytes in a sample. The present invention further provides kits and systems for detecting antigen-specific T lymphocytes in a sample.

Claims (15)

1. A method of detecting an antigen-specific T lymphocyte in a sample, the method comprising:

a) combining a cell sample comprising a T lymphocyte with an isolated antigen, an IL-15 receptor agonist, and an IL-7 receptor agonist, forming a test sample, wherein the IL-15 receptor agonist is naturally occurring IL-15, recombinant IL-15, or synthetic IL-15, and wherein the IL-7 receptor agonist is naturally occurring IL-7, recombinant IL-7, or synthetic IL-7; and

b) detecting a T lymphocyte specific for the antigen in the test sample.

2. The method of claim 1 , wherein the detecting step comprises detecting interferon-gamma (IFN-γ) secreted by the antigen-specific T lymphocyte.

3. The method of claim 1 , wherein the IFN-γ is detected by capturing IFN-γ on a solid support, and detecting the captured IFN-γ with an antibody specific for IFN-γ.

4. The method of claim 1 , wherein the antigen is an allergen.

5. The method of claim 1 , wherein the antigen is an antigen associated with a pathogenic microorganism.

6. The method of claim 1 , wherein the antigen is an autoantigen.

7. The method of claim 1 , wherein the antigen is a tumor-associated antigen.

8. The method of claim 1 , wherein the antigen-specific T lymphocyte is a CD4 + T lymphocyte.

9. The method of claim 1 , wherein the antigen-specific T lymphocyte is a CD8 + T lymphocyte.

10. The method of claim 1 , further comprising, in step (a), combining the cell sample with an antibody that binds a Class I MHC polypeptide, thereby reducing detection of CD8 + T lymphocytes in the sample.

11. The method of claim 1 , further comprising, in step (a), combining the cell sample with an antibody that binds a Class II MHC polypeptide, thereby reducing detection of CD4 + T lymphocytes in the sample.

12. The method of claim 1 , wherein the antigen is at least 80% pure.

13. The method of claim 1 , wherein the antigen is synthetic.

Assignments (3)
CONFIRMATORY LICENSE Recorded Apr 18, 2017
From: J. DAVID GLADSTONE INSTITUTES
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 042046/0158 →
CONFIRMATORY LICENSE Recorded Oct 8, 2009
From: J. DAVID GLADSTONE INSTITUTES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023337/0683 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2004
From: NIXON, DOUGLAS; SHACKLETT, BARBARA; JENNES, WIM; KESTENS, LUC
To: THE J. DAVID GLADSTONE INSTITUTES
Reel/Frame 015495/0817 →
Continuity (2)
Provisional Application 6049122500 · Jul 29, 2003
Related Publication 20050074822A1 · Apr 7, 2005